[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-364017-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-364017-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pan-cancer-prioritization-of-ccdc69-reveals-an-immune-enriched-and-therapeutically-sensitive-breast-cancer-phenotype","Pan-cancer prioritization of CCDC69 reveals an immune-enriched and therapeutically sensitive breast cancer phenotype","","Coiled-coil domain-containing protein 69 (CCDC69) is implicated in tumor biology, yet its pan-cancer immunogenomic landscape and significance for breast cancer were unclear. Integrating TCGA and GTEx transcriptomes, paired tumor-normal comparisons, diagnostic and survival modeling, multi-omic profiling, immunecycles, immune infiltration, single-cell and spatial data, pathway enrichment, immunotherapy cohorts, pharmacogenomic resources, and molecular docking, the study characterizes CCDC69 across cancers and BRCA.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pan-cancer-prioritization-of-ccdc69-reveals-an-immune-enriched-and-therapeutically-sensitive-breast-cancer-phenotype/364017/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pan-cancer-prioritization-of-ccdc69-reveals-an-immune-enriched-and-therapeutically-sensitive-breast-cancer-phenotype/364017.png","ImageObject",300,407,{"name":42,"@type":43},"OmBimo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-20","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of this study?","Question",{"text":63,"@type":64},"To define the pan-cancer immunogenomic context of CCDC69 and determine its relevance to breast invasive carcinoma (BRCA).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which datasets and analytical approaches were integrated?",{"text":68,"@type":64},"The study combined TCGA and GTEx transcriptomes, tumor-normal comparisons, diagnostic and survival analyses, copy-number/genomic instability profiling, immunecycle and immune-infiltration analyses, single-cell and spatial transcriptomics, pathway enrichment, immunotherapy cohorts, pharmacogenomic resources, and molecular docking.",{"name":70,"@type":61,"acceptedAnswer":71},"What key finding links CCDC69 to breast cancer risk and immunity?",{"text":72,"@type":64},"Higher CCDC69 expression in BRCA correlated with less advanced clinicopathological features, immune-enriched microenvironments, higher cancer-immunity-cycle activity, diverse immune-cell infiltration, and pathway patterns consistent with immune activation and interferon response.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},364017,1790303998,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090893581,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Chen et al. Discover Oncology (2026) 17:1209 Discover Oncology  \n[https://doi.org/10.1007/s12672-026-05476-1](https://doi.org/10.1007/s12672-026-05476-1)  \nANALYSIS Open Access  \nPan-cancer prioritization of CCDC69 reveals an  immune-enriched and therapeutically sensitive breast cancer phenotype  \nYi Chen1†, Boyang Li1,2†, Jinghao Pan2, Ruonan Lin2, Lucy Yue Lau3, Boxiang Zhang1, Kuan Wang1, Chenlu Fang2, Wenjia Guo1* and Zehao Hong1,2*  \n†Yi Chen and Boyang Li have contributed equally to this work.  \n*Correspondence:  \nWenjia Guo[wenjiaguoxjmu@163.com](wenjiaguoxjmu@163.com)[ ](wenjiaguoxjmu@163.com)Zehao Hong [HongZehaoZZU@outlook.com](HongZehaoZZU@outlook.com)[ ](HongZehaoZZU@outlook.com)1Cancer Research Institute, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China 2The First Clinical School of Medicine, Zhengzhou University, Zhengzhou 450052, Henan, China 3Department of Public Health, Harvard Medical School, Boston, MA 02115, USA  \nAbstract  \nBackground Coiled-coil domain-containing protein 69 (CCDC69) has been implicated in tumor biology, but its pan-cancer immunogenomic context and relevance to breast cancer remain insufficiently defined.  \nMethods We integrated The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) transcriptomes, paired tumor-normal comparisons, diagnostic modeling, survival analyses, copy-number and genomic-instability profiling, immunecycle and immune-infiltration analyses, single-cell and spatial transcriptomic datasets, pathway enrichment, immunotherapy cohorts, pharmacogenomic resources and molecular docking to characterize CCDC69 across cancers and in breast invasive carcinoma (BRCA) .  \nResults CCDC69 was broadly dysregulated across cancers and showed cancer-typedependent diagnostic value. Pan-cancer survival analyses revealed context-specific prognostic effects, with BRCA showing consistent favorable associations for diseasespecific survival (DSS), disease-free interval (DFI) and progression-free interval (PFI) . Further analyses linked CCDC69 to copy-number states, stemness, genomic instability and multiple immune phenotypes. Integrated prioritization highlighted BRCA as a representative tumor context. In BRCA, higher CCDC69 expression was associated with less advanced clinicopathological features, immune-enriched microenvironments, increased cancer-immunity-cycle activity, diverse immune-cell infiltration and compartment-specific expression across tumor, immune and stromal regions. Pathway analyses connected CCDC69 with immune activation, interferon response and lymphocyte-related programs, while showing inverse associations with proliferation, DNA repair and cell-cycle signatures. Immunotherapy and drug-sensitivity analyses suggested context-dependent response-stratification and therapeutic relevance. Conclusion CCDC69 delineates an immune-active, favorable-risk BRCA state with potential prognostic and therapy-related value, warranting experimental and clinical validation.  \nKeywords CCDC69, Breast cancer, Pan-cancer analysis, Prognostic biomarker, Immunotherapy response  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation ","cbCairlUjoDyRY8u","https://ap.wps.com/l/cbCairlUjoDyRY8u","pdf",7645711,26,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Breast cancer heterogeneity and biomarker need\n## Cancer-immunity cycle and immune microenvironment","[{\"question\":\"What was the main goal of this study?\",\"answer\":\"To define the pan-cancer immunogenomic context of CCDC69 and determine its relevance to breast invasive carcinoma (BRCA).\"},{\"question\":\"Which datasets and analytical approaches were integrated?\",\"answer\":\"The study combined TCGA and GTEx transcriptomes, tumor-normal comparisons, diagnostic and survival analyses, copy-number/genomic instability profiling, immunecycle and immune-infiltration analyses, single-cell and spatial transcriptomics, pathway enrichment, immunotherapy cohorts, pharmacogenomic resources, and molecular docking.\"},{\"question\":\"What key finding links CCDC69 to breast cancer risk and immunity?\",\"answer\":\"Higher CCDC69 expression in BRCA correlated with less advanced clinicopathological features, immune-enriched microenvironments, higher cancer-immunity-cycle activity, diverse immune-cell infiltration, and pathway patterns consistent with immune activation and interferon response.\"}]","Pan-cancer prioritization of CCDC69 reveals an immune-enriched and therapeutically sensitive breast cancer phenotype | PDF",1790155142,66,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99d202afc358a831e901d7fafd03aef9.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4aa4566e1ccf81ba8f57213d0790a94a.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/301b959261f5a5b24ee5f6ceea43de79.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e6f159a242ee4e73ed11a025d8c826b4.webp",980,1306]